daniel cohenDear Sir, Dear Madam, Dear Shareholder,

We would like to thank all of our shareholders, both historical and new, for the trust they have placed in us and their decision to accompany Pharnext in the development of a disruptive new approach: a new generation of drugs which will offer greater effectiveness and safety to a larger number of patients.

The pharmaceutical sector is now facing numerous challenges such as higher prices of drugs or higher failure rates in the development of a new drug. Faced with these challenges, we are proposing a new breakthrough approach to better treat a far larger number of patients at an affordable cost: PLEOTHERAPY.

Developed over the last 30 years, this concept is a new paradigm recognized by internationally renowned scientists, including several Nobel Prizes. PLEOTHERAPY differs from monotherapy, which focuses on a single therapeutic target, by allowing the treatment of several targets at the same time thanks to PLEODRUG. These are synergistic lower dose combinations of drugs that have already been used for other diseases and have a known tolerance profile. PLEODRUG present numerous advantages: an excellent safety profile and effectiveness, as well as far-reaching and solid intellectual property. In addition, the use of already approved molecules considerably reduces the duration and cost of developing a PLEODRUG compared with a conventional drug.

Pharnext’s objective is to become the champion of drugs’ repositioning and combinations. To demonstrate the suitability of this approach, we have chosen to start working on diseases with high unmet medical needs and no satisfactory treatment to date: Charcot-Marie-Tooth type 1A disease and Alzheimer’s disease.

We are currently developing two candidate products. Proof of the concept has been established in Charcot-Marie-Tooth type 1A with PXT3003: positive results have been obtained in Phase 2 and two international Phase 3 clinical trial are ongoing in Europe and the United States. Our second product, PXT864, has generated positive Phase 2 in Alzheimer’s disease. We currently foresee other indications as PLEOTHERAPY can potentially be applied to any disease, despite the fact that the company is currently focusing on neurodegenerative diseases.

We are committed to developing new safe and effective therapies for patients suffering from rare diseases. To Pharnext, every patient counts and deserves the very best therapeutic solutions.

Daniel Cohen
Founder & CEO